BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bizrolertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bizrolertinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05593094-11326@assetmemo.bio
DTSTAMP:20261121T005949Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Bizrolertinib: Phase 1/2 readout est. (NCT05593094)
DESCRIPTION:Bizrolertinib\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy
 : A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Particip
 ants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advance
 d Solid Tumors\nEstimated primary completion: 31 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/bizrolertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05593094
URL:https://assetmemo.bio/drug/bizrolertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413939-11326@assetmemo.bio
DTSTAMP:20261121T005949Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Bizrolertinib: Phase 2/3 readout est. (NCT07413939)
DESCRIPTION:Bizrolertinib\, phase 2/3\, HER2-Positive Breast Cancer.\nStudy
 : RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitab
 ine in People With Locally Advanced or Metastatic Breast Cancer That is Hu
 man Epidermal Growth Factor Receptor 2 (HER2)-Positive\nEstimated primary 
 completion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bizrolertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07413939
URL:https://assetmemo.bio/drug/bizrolertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
